NEW
HAVEN, Conn., Sept. 22,
2022 /PRNewswire/ -- Trevi Therapeutics, Inc.
(Nasdaq: TRVI), a clinical-stage biopharmaceutical company
developing an investigational therapy, Haduvio™ (oral
nalbuphine ER) for the treatment of chronic cough in adults with
idiopathic pulmonary fibrosis (IPF) and the treatment of prurigo
nodularis (PN), today announced that it has commenced an
underwritten public offering of shares of its common stock (or
pre-funded warrants to purchase common stock in lieu thereof). All
of the shares and pre-funded warrants are being offered by Trevi.
In addition, Trevi expects to grant the underwriters a 30-day
option to purchase shares of common stock equal to up to 15% of the
number of securities sold in the public offering at the public
offering price, less underwriting discounts and commissions.
SVB Securities, Stifel and Oppenheimer & Co. are acting as
joint bookrunning managers for the offering. Needham &
Company is acting as lead manager for the offering. The offering is
subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
The shares and pre-funded warrants are being offered by Trevi
pursuant to a shelf registration statement that was filed with the
Securities and Exchange Commission ("SEC") on June 26, 2020 and declared effective by the SEC
on July 2, 2020.
This offering is being made only by means of a prospectus and
prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement relating to and
describing the terms of the offering is expected to be filed with
the SEC and, when filed, copies of the preliminary prospectus
supplement relating to the offering may be obtained for free by
visiting the SEC's website at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus
may also be obtained from SVB Securities LLC, Attention: Syndicate
Department, 53 State Street, 40th Floor, Boston, MA 02109 by email at
syndicate@svbsecurities.com or by phone at (800) 808-7525, ext.
6105; Stifel, Nicolaus & Company, Incorporated, Attention:
Syndicate, One Montgomery Street,
Suite 3700, San Francisco, CA
94014, by telephone at 415-364-2720 or by email at
syndprospectus@stifel.com; or Oppenheimer & Co. Inc., 85 Broad
Street, 26th Floor, New York, NY
10004, Attn: Syndicate Prospectus Department, telephone: (212)
667-8055 or by email at EquityProspectus@opco.com. The final terms
of the offering will be disclosed in a final prospectus supplement
to be filed with the SEC.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and commercialization of the
investigational therapy Haduvio for the treatment of chronic cough
in adults with idiopathic pulmonary fibrosis and prurigo nodularis.
These conditions share a common pathophysiology that is mediated
through opioid receptors in the central and peripheral nervous
systems.
Founded in 2011, Trevi is headquartered in New Haven,
CT.
Forward-Looking Statements
Statements contained in this press release regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties and
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such statements
include, but are not limited to, statements about the anticipated
public offering, and other statements containing the words
"believes," "anticipates," "plans," "expects," and similar
expressions. Risks that contribute to the uncertain nature of the
forward-looking statements include: uncertainties related to market
conditions and the completion of the public offering on the
anticipated terms or at all, as well as other risks and
uncertainties set forth in the "Risk Factors" section of the
preliminary prospectus supplement to be filed with the SEC, in
Trevi's quarterly report on Form 10-Q for the quarter ended
June 30, 2022 filed with the SEC, and
in any subsequent filings with the SEC. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Trevi undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made
except as required by law.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-proposed-public-offering-301631588.html
SOURCE Trevi Therapeutics, Inc.